Aerosol Inhalation Treatment for Dyspnea

Phase 1/2 Completed 24 enrolled Beth Israel Deaconess Medical Center National Institute of Nursing Research (NINR) · collab

RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this protocol is to develop and test optimal delivery of aerosol furosemide, a treatment that has the potential to significantly improve symptom management and enhance the quality of care for patients with intractable dyspnea.

Timeline

Start: 2011-09
Primary completion: 2016-04
Completion: 2017-04

Outcome

Missed primary endpoint

registry analysis (superiority test); Aerosol Furosemide (40 mg) vs Aerosol Saline (4 ml); p = 0.99; t-test, 2 sided NCT01440764 ↗

registry analysis (superiority test); Aerosol Furosemide (80mg) vs Aerosol Saline (8 ml); p = 0.32; t-test, 2 sided NCT01440764 ↗

Publications

Background Banzett RB, Adams L, O'Donnell CR, Gilman SA, Lansing RW, Schwartzstein RM. Using laboratory models to test treatment: morphine reduces dyspnea and hypercapnic ventilatory response. Am J Respir Crit Care Med. 2011 Oct 15;184(8):920-7. doi: 10.1164/rccm.201101-0005OC. Epub 2011 Jul 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Furosemide	Other / unclassified	15 mg	Inhaled
Subject	Furosemide	Other / unclassified	40 mg	Inhaled
Subject	Furosemide	Other / unclassified	80 mg	Inhaled

Indications

No indication recorded.